Azerbaijan National Academy of Sciences

On March 16, at the Kaiser Permanente Seattle Washington Health Research Institute in Seattle, the first volunteer group member received a dose of experimental vaccine.

The vaccine, called mRNA-1273, was developed at Moderna Inc, a biotechnology company with the participation of the United States National Institutes of Health (NIH). It will receive 45 healthy adults aged 18 to 55 years. In the first phase of testing, researchers will evaluate the safety of the vaccine for humans. There is no risk of contracting the SARS-Cov-2 virus at this stage.

Representatives of a public health organization in the United States estimated the timing of a complete vaccine screening. To confirm the safety and protective properties of the drug, it will take from one to one and a half years, the test data of thousands of people will be needed. Despite the upcoming scope of work, researchers consider these terms to be very optimistic.

popmech.ru